Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 06/20/2025 | CALL | $155.00 | 3,000 | +2,000 | +200.00% |
| 06/20/2025 | PUT | $155.00 | 3,000 | +2,000 | +200.00% |
| 03/20/2026 | PUT | $90.00 | 620 | +620 | |
| 01/16/2026 | PUT | $90.00 | 702 | +603 | +609.09% |
| 01/15/2027 | PUT | $165.00 | 572 | +546 | +2,100.00% |
| 05/02/2025 | CALL | $157.50 | 3,075 | +371 | +13.72% |
| 06/20/2025 | CALL | $160.00 | 11,748 | -433 | -3.55% |
| 05/16/2025 | CALL | $165.00 | 7,290 | -468 | -6.03% |
| 09/19/2025 | CALL | $190.00 | 1,350 | -603 | -30.88% |
| 05/16/2025 | CALL | $160.00 | 10,705 | -796 | -6.92% |
| 05/02/2025 | CALL | $162.00 | 4,000 | -2,000 | -33.33% |
| 05/02/2025 | PUT | $162.00 | 4,000 | -2,000 | -33.33% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
| Name | Pct Held | Shares | Total |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.55% | 79.47M | 12.56B |
| Vanguard 500 Index Fund | 1.94% | 60.44M | 9.55B |
| Fidelity 500 Index Fund | 0.92% | 28.66M | 4.53B |
| SPDR S&P 500 ETF Trust | 0.91% | 28.31M | 4.47B |
| iShares Core S&P 500 ETF | 0.75% | 23.33M | 3.69B |
| Vanguard Index-Value Index Fund | 0.72% | 22.6M | 3.57B |
| Select Sector SPDR Fund-Health Care | 0.68% | 21.24M | 3.36B |
| Vanguard Institutional Index Fund-Institutional Index Fund | 0.59% | 18.32M | 2.9B |
| Vanguard Specialized-Dividend Appreciation Index Fund | 0.53% | 16.62M | 2.63B |
| Washington Mutual Investors Fund | 0.40% | 12.37M | 1.96B |
Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash?
05/04 04:49 am
The Motley Fool
Read moreAnalysis of Cancer Immunotherapy Technologies and Global Markets to 2029 - Merck, Roche, Bristol-Myers Squibb Company, Johnson & Johnson Services, and AstraZeneca Dominate
04/30 04:56 am
GlobeNewswire Inc.
Read moreLe TAR-200 en monothérapie de Johnson & Johnson présente le taux de réponse complète le plus élevé rapporté à ce jour avec des bénéfices cliniques durables chez les patients atteints de certains types de cancer de la vessie
04/29 06:00 am
GlobeNewswire Inc.
Read more3 Industry Behemoths Are Rewarding Investors With Dividend Bumps
04/28 01:22 pm
Investing.com
Read moreJohnson & Johnson’s TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC
04/26 02:00 pm
GlobeNewswire Inc.
Read moreJohnson & Johnson’s TAR-200 monotherapy demonstrates highest complete response rate reported to date with sustained clinical benefits in patients with certain types of bladder cancer
04/26 01:50 pm
GlobeNewswire Inc.
Read moreThese 2 Top Dividend Stocks Are Making Moves to Avoid the Impact of Tariffs: Are They Buys?
04/26 10:15 am
The Motley Fool
Read moreTREMFYA® (guselkumab) receives European Commission approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson’s leadership in inflammatory bowel disease
04/25 03:00 am
GlobeNewswire Inc.
Read more3 Dividend Kings That Have Raised Their Payouts in 2025
04/24 08:34 am
The Motley Fool
Read moreIs Target Stock's High Yield Worth It in 2025?
04/24 05:25 am
The Motley Fool
Read moreIn the Wake of the Trump Tariff Crash: 2 Unparalleled Dividend Stocks to Buy at a Discount Right Now
04/24 03:51 am
The Motley Fool
Read moreRoche Plans $50 Billion US Investment Over 5 Years With 12,000 New Jobs
04/22 03:21 pm
Benzinga
Read more2 Recession-Proof Stocks to Buy With a Better Credit Rating Than the U.S. Government
04/20 07:30 am
The Motley Fool
Read more3 Top Dividend Stocks Yielding Over 3% to Buy With $500 Right Now
04/19 10:30 am
The Motley Fool
Read more4 Reasons Johnson & Johnson Could Be the Perfect Stock to Own in Today's Turbulent Market
04/17 04:51 am
The Motley Fool
Read moreMiastenia gravis generalizzata (gMG): Johnson & Johnson mette in luce nuovi dati che dimostrano il controllo sostenuto di malattia a lungo termine nei soggetti adulti affetti
04/16 10:50 am
GlobeNewswire Inc.
Read moreJohnson & Johnson Q1 Earnings: Strong Cancer Drug Sales, Boosts Quarterly Dividend, Anticipates Negative Currency Impact For 2025 Profit
04/15 09:09 am
Benzinga
Read moreNovartis Commits $23 Billion To Expand US Manufacturing Over Five Years, Despite Tariffs Uncertainties
04/11 09:36 am
Benzinga
Read more2 Top Dividend Stocks to Buy Right Now
04/11 04:25 am
The Motley Fool
Read moreBiopharmaceuticals Global Overview Report 2025: Global Market to Reach $698.7 Billion by 2030, Fueled by Specialized Therapies, Such as mAb and Gene Treatments, & a Strong Pipeline
04/10 05:59 am
GlobeNewswire Inc.
Read moreThe Dow Crashed 4,260 Points in 3 Days: Here Are 3 Dow Stocks That Make for No-Brainer Buys Right Now
04/10 03:51 am
The Motley Fool
Read moreIntramedullary Nail Market size to worth USD 1,537 Million by 2032, says Coherent Market Insights
04/10 01:30 am
GlobeNewswire Inc.
Read moreJohnson & Johnson's New 'Compelling Data' Shows Sustained Symptom Improvement In Muscular Disease Patients
04/08 02:26 pm
Benzinga
Read more2 Defensive Sectors to Protect Your Portfolio During a Recession
04/08 08:17 am
Investing.com
Read moreOphthalmology Market Report 2025 | Industry to Reach US$93.7 Billion by 2030 | Emerging Research Activities of Ophthalmology Treatments and Availability of Grants Present Business Opportunities
04/08 04:52 am
GlobeNewswire Inc.
Read moreGlobal Cosmeceuticals Market Size to Reach USD 182.17 Bn by 2032, at a CAGR of 9.6%, says Coherent Market Insights
04/08 12:50 am
GlobeNewswire Inc.
Read moreAll the Stocks Warren Buffett Bought in the Last 2 Recessions: Are They Smart Picks Now?
04/06 04:46 am
The Motley Fool
Read morePresident Trump's Tariffs Have Arrived. 3 Things to Do to Protect Your Portfolio.
04/05 03:40 am
The Motley Fool
Read moreTrump's Tariff Exemptions Include Semiconductors, Pharmaceuticals, Oil And More
04/03 12:30 pm
Benzinga
Read moreWorried About the Economy? 2 No-Brainer Buys to Shield Your Portfolio.
04/02 06:15 pm
The Motley Fool
Read moreWhy Johnson & Johnson Stock Is Sinking Today
04/01 02:38 pm
The Motley Fool
Read moreInternet of Medical Things (IoMT) Market Forecast 2024-2029 & 2034 - Revenues to Grow from US$97.73 Billion in 2025 to US$244.4 Billion by 2029
03/27 10:59 am
GlobeNewswire Inc.
Read more2 Recession-Proof Dividend Stocks to Buy and Hold
03/27 05:25 am
The Motley Fool
Read moreJ&J Drug Combo Outperforms Leading Lung Cancer Treatment In Survival Study
03/26 02:40 pm
Benzinga
Read morePharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
03/21 12:31 pm
Benzinga
Read moreHoneywell Isn't Going to Let a Little Breakup Ruin Its Growth Plans
03/20 04:45 am
The Motley Fool
Read moreFDA Grants Fast Track Review To Johnson & Johnson's Nipocalimab For Autoimmune Disorder That Affects Tears, Saliva
03/18 12:17 pm
Benzinga
Read moreGot $300? Buy These 3 Top Dividend Stocks and Never Look Back.
03/18 04:34 am
The Motley Fool
Read moreAC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update
03/13 07:00 am
GlobeNewswire Inc.
Read moreBispecific Antibody Market Opportunity, Drug Dosage, Patent, Price, Sales & Clinical Trials Insight 2030: New Report Highlights 600+ Bispecific Antibodies in Clinical Trials Worldwide
03/12 08:48 am
GlobeNewswire Inc.
Read moreIs the Vanguard High Dividend Yield ETF the Smartest Investment You Can Make Today?
03/10 06:11 am
The Motley Fool
Read moreGlobal Operating Room Equipment Market is Predicted to Cross ~USD 40 Billion by 2032 | DelveInsight
03/04 02:00 pm
GlobeNewswire Inc.
Read moreBALVERSA Adoption on the Rise: Meeting Unmet Needs in Advanced Urothelial Cancer | DelveInsight
03/04 02:00 pm
GlobeNewswire Inc.
Read more2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies
03/04 11:55 am
GlobeNewswire Inc.
Read more3 Top High-Yield Dividend Stocks I Plan to Buy in March for More Passive Income
03/02 08:38 am
The Motley Fool
Read moreInternational Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month
03/01 09:45 am
GlobeNewswire Inc.
Read more3 Dividend Stocks That Are No-Brainer Buys Right Now
03/01 06:51 am
The Motley Fool
Read moreJohnson & Johnson’s DARZALEX® (daratumumab) subcutaneous-based regimen receives positive CHMP opinion for patients with newly diagnosed multiple myeloma, regardless of transplant eligibility
02/28 09:01 am
GlobeNewswire Inc.
Read moreWall Street's Greatest Dividend Stock Just Made History Again -- and 99.9% of Investors Have Never Heard of This Small-Cap Company
02/28 06:06 am
The Motley Fool
Read moreLatin American Remote Tech Talent Expands: BairesDev Sees 285% Surge in Remote Applicants in 2024
02/27 09:00 am
GlobeNewswire Inc.
Read more